STR reported a lower than expected performance in 2QFY22 due to continued headwinds in the US business. Sales in other regulated markets witnessed a recovery, with an 18% YoY growth. With the completion of Endo products and facility acquisition, STR will have a diversified US portfolio, with a lower proportion of Acute products as well as differentiated products such as hormones, Nasal Sprays, Gels, Modified Release products, and controlled substances, which are less susceptible to price shocks like that seen in 1HFY22. Other regulated/emerging markets are...